Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSO100201200013I
Award Date
9/1/12
Last Date to Order
8/31/16
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
Contract IDVs
Contract Awards
7
Transactions
6
Price Lists
Opportunity Stack
1
Federal Agency
Office of the Assistant Secretary for Preparedness and Response
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325414 - Biological Product (except Diagnostic) Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pandemic Influenza Preparedness and Response 2012-2016
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Pandemic Influenza Preparedness and Response 2012-2016
Master IDIQ
HHSO100201200013I
Indefinite Delivery Contract
7
Federal Contract Awards
Description
Update #1
Update #2
Update #3
DRUGS AND BIOLOGICALS
Posted 8/31/12, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
5
MCMS - COR CHANGE
Other Administrative Action
$0
1/29/16
4
MCMS - OPTION EXERCISE
Exercise an Option
$0
7/22/15
3
REVISE G.2
Other Administrative Action
$0
5/19/15
2
ACQUISITION OF MCMS FOR PANDEMIC INFLUENZA PREPAREDNESS AND RESPONSE
Other Administrative Action
$0
8/26/14
1
ACQUISITION OF MCMS FOR PANDEMIC INFLUENZA PREPAREDNESS AND RESPONSE
Other Administrative Action
$0
8/15/14
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSO100201200013I-HHSO10033004T
This is a firm fixed price delivery order awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Glaxosmithkline, LLC, a pharmaceutical company, for the production of influenza vaccine master and working seed lots. The contract is part of the Pandemic Influenza Preparedness and Response 2012-2016 program and has a potential value of $533,988.00. There is no set-aside designation for this award. The contract supports the agency's efforts to acquire materials for pandemic influenza preparedness and response.
Glaxosmithkline, LLC
$534.0k
4/26/13
7/25/13
4/4/24
Delivery Order HHSO100201200013I-HHSO10033007T
ASPR-14-01155 -- GSK SHELF LIFE EXTENSIONS OF THE QUEBEC H5N1 DRUG SUBSTANCE BATCHES CURRENTLY STORED IN HYCLONE CX5-14 BAGS UNDER CONTRACT HHSO100201200014I
Glaxosmithkline, LLC
$0
9/10/14
3/31/17
11/2/16
Delivery Order HHSO100201200013I-HHSO10033003T
This is a delivery order awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to GlaxoSmithKline, LLC, a pharmaceutical company, under the Pandemic Influenza Preparedness and Response 2012-2016 contract. The contract is for the production of non-GMP influenza vaccine plots at a firm fixed price of $149,412.00. The award supports ASPR's broader efforts for pandemic influenza preparedness and response, including disease prevention, immunization programs, and drug stockpiling initiatives. The contract has no set-aside designation and the work will be performed at GlaxoSmithKline's facilities in Research Triangle Park, North Carolina.
Glaxosmithkline, LLC
$149.4k
2/27/13
9/26/13
4/9/24
Delivery Order HHSO100201200013I-HHSO10033008T
This is a firm fixed price delivery order awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Glaxosmithkline, LLC for the storage of H5N1 antigen bulk lots and final containers, as well as adjuvant bulk lots and final containers, for calendar year 2015. The order is part of the Pandemic Influenza Preparedness and Response 2012-2016 contract, with a ceiling value of $2,953,288.95. The contract has no set-aside designation and the place of performance is in Ottawa, Canada. This award supports the agency's ACQUISITION OF MCMS FOR PANDEMIC INFLUENZA PREPAREDNESS AND RESPONSE program.
Glaxosmithkline, LLC
$3.0m
4/3/15
8/31/16
1/9/25
Delivery Order HHSO100201200013I-HHSO10033006T
This federal contract award, valued at $7,168,961.00, was issued by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to the prime contractor Glaxosmithkline, LLC for the acquisition of Medical Countermeasures and Systems (MCMS) to support pandemic influenza preparedness and response. The contract is a delivery order under the Pandemic Influenza Preparedness and Response 2012-2016 indefinite delivery vehicle, with a firm fixed price pricing type. The place of performance is Research Triangle Park, North Carolina. Glaxosmithkline, a pharmaceutical company that provides vaccines, antivirals, and other products to government agencies, has supported various disease prevention, immunization, and correctional healthcare efforts through prior federal contracts and grants.
Glaxosmithkline, LLC
$7.2m
8/16/13
8/15/15
4/9/24
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
Acquisition of MCMs for Pandemic Influenza Preparedness and Response
Added: Jan 31, 2012 11:24 am THIS IS A PRESOLICITATION NOTICE ONLY.Human influenza pandemics continue to be a public health concern. Four human influenza pandemics have occurred in the past century. BARDA has recently completed the preparation and response to the 2009 H1N1 pandemic influenza virus. The WHO estimates approximately 59% case fatality of the currently circulating H5N1 avian influenza virus. At this time it is uncertain which influenza virus variant will cause the next pandemic. The BARDA Strategic Plan 2011-2016 outlines the approach to enhance national MCM preparedness and response. BARDA plans to continue the programs for the development and procurement of MCM for pandemic influenza preparedness and response. To accomplish this goal, BARDA intends to publish a Request for Proposals for the supply of the following items and/or services: pre-pandemic master/working virus seeds; pre-pandemic and pandemic pilot, clinical and commercial bulk vaccines and adjuvants; storage and stability studies of vaccines and adjuvants; formulation-fill-finish of vaccine and adjuvants; preclinical and clinical studies with pre-pandemic and pandemic vaccine; international shipping; storage services and stability program for vaccine and adjuvants, (bulk and final containers) from current contracts when applicable; and disposal of vaccine bulk and final containers. The Department of Health and Human Services through the Biomedical Advanced Research and Development Authority (BARDA) contemplates single or multiple awards of contracts to companies that meet the following mandatory criteria: The offeror shall produce vaccines against influenza and influenza strains with pandemic potential; shall demonstrate a successful experience in the manufacturing of influenza vaccine by: • Holding a US influenza vaccine license OR • Have developed an influenza vaccine as evidenced by: o A complete final Phase 3 clinical study report AND o A documented BLA in preparation. The anticipated period of performance will be for a total of up to five (5) years or sixty (60) months with a potential for two (2) one (1) year option periods. Additional details and requirements will be described in the solicitation. A Request for Proposal (RFP) will be available electronically through the Federal Business Opportunities (FedBizOpps) website (www.fbo.gov) on or about February 14, 2012, with proposals being due on or about April 2, 2012.Any responsible offeror may submit a proposal that will be considered by the Government. This notice does not commit the Government to the award of a contract. It is the offeror's responsibility to monitor this website (www.fbo.gov) for the release of the solicitation as well as any amendments to the solicitation. Potential offerors will be responsible for downloading their own copy of the solicitation and any amendments via this website. No collect calls will be accepted. No facsimile transmissions will be accepted. All responses and/or inquiries concerning this requirement MUST be identified with the RFP number, name of firm, name of requestor, mailing address, telephone number, fax number, email address and should be submitted to the primary and/or secondary point of contact identified in this notice.Multiple awards may result from this solicitation with an estimated award date of August 2012.
11-100-SOL-00020
Department of Health and Human Services Immediate Office of the Secretary
Award Notice 1/1
1/31/12, 11:24 AM